Form 4: Twist Bioscience CEO Emily Leproust Reports Stock Transactions
SEC Form 4 Filing
Twist Bioscience CEO Emily Leproust reported the acquisition of 95,350 shares of common stock and various transactions related to employee stock options.
Summary
- Emily M. Leproust, CEO of Twist Bioscience, filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
- She acquired 95,350 shares of common stock through a restricted stock unit award, with vesting occurring quarterly over 48 months starting November 20, 2024.
- The filing also includes details of various employee stock options, some of which are immediately exercisable and others that vest over time based on continued service.
- Some options have already vested due to performance criteria being met.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing, indicating normal business operations and executive compensation practices. There is no indication of positive or negative sentiment.
Positives
- The acquisition of shares through restricted stock units aligns the CEO's interests with the long-term performance of the company.
- The vesting schedules of the stock options incentivize continued service and performance from the CEO.
Industry Context
Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the trading activities of company insiders.
Comparison to Industry Standards
- The vesting schedules for stock options and restricted stock units are typical for executive compensation packages in the biotechnology industry.
- The reporting of these transactions is consistent with SEC regulations for insider trading.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the CEO's stock ownership and compensation.
Key Dates
| Date | Description |
|---|---|
| 09/01/2016 | 25% of shares subject to one option vested. |
| 09/28/2017 | 10% of shares subject to one option vested. |
| 09/28/2018 | 15% of shares subject to one option vested. |
| 10/31/2019 | 20% of shares subject to one option vested. |
| 10/24/2020 | 25% of shares subject to one option vested. |
| 12/19/2022 | Performance stock options vested and became exercisable. |
| 11/20/2024 | Start date for quarterly vesting of restricted stock units. |
| 12/04/2024 | Date of the reported transactions. |
| 12/06/2024 | Date of signature on the Form 4. |
Keywords
Form 4, Twist Bioscience, Emily Leproust, stock options, restricted stock units, insider trading, beneficial ownership, equity securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.